A number of research firms have changed their ratings and price targets for Cyclacel Pharmaceuticals (NASDAQ: CYCC):

  • 9/18/2018 – Cyclacel Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “CYCLACEL is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine, a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and cutaneous T-cell lymphoma. Seliciclib (CYC202 or R-roscovitine), a CDK inhibitor, is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer. “
  • 9/11/2018 – Cyclacel Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “CYCLACEL is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine, a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and cutaneous T-cell lymphoma. Seliciclib (CYC202 or R-roscovitine), a CDK inhibitor, is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer. “
  • 9/7/2018 – Cyclacel Pharmaceuticals is now covered by analysts at LADENBURG THALM/SH SH. They set a “buy” rating and a $6.25 price target on the stock.
  • 9/5/2018 – Cyclacel Pharmaceuticals is now covered by analysts at Roth Capital. They set a “buy” rating and a $8.00 price target on the stock.
  • 8/10/2018 – Cyclacel Pharmaceuticals was given a new $7.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.

NASDAQ CYCC traded down $0.01 during trading on Wednesday, reaching $1.35. The company’s stock had a trading volume of 405 shares, compared to its average volume of 88,702. Cyclacel Pharmaceuticals Inc has a twelve month low of $1.28 and a twelve month high of $2.25.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last issued its earnings results on Thursday, August 9th. The biotechnology company reported ($0.16) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.04). equities analysts anticipate that Cyclacel Pharmaceuticals Inc will post -0.63 earnings per share for the current year.

A hedge fund recently raised its stake in Cyclacel Pharmaceuticals stock. Renaissance Technologies LLC grew its position in Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) by 513.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 91,400 shares of the biotechnology company’s stock after acquiring an additional 76,500 shares during the period. Renaissance Technologies LLC owned about 0.76% of Cyclacel Pharmaceuticals worth $130,000 at the end of the most recent quarter. Institutional investors own 5.61% of the company’s stock.

Cyclacel Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes.

See Also: Analyst Ratings

Receive News & Ratings for Cyclacel Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.